Valeant Pharmaceuticals (VRX.TO) Buy, Sell or…

Valeant Pharmaceuticals (VRX.TO)

0.00

-0.00 (0.00%)

39 watching

DON'T BUY

A good company and profitable. Not a fan of management. Some questions on their accounting. Earnings have been disappointing. Would be a stunning buy at $18. Would consider at $23.

WAIT

Would wait to see the results of the inquiry of the SEC. The air needs to be cleared.

DON'T BUY

Very controversial because of their reporting practices. Have great upside potential but with the SCC involved and the murkiness around the company it’s really a black box.

DON'T BUY

Still in the “pray and hope” stage. Below a 200-day moving average.

DON'T BUY

There's an issue around the credibility of management. $20 stock price would make the risk more worthwhile.

DON'T BUY

Accounting irregularities? Company has never generated profitability.

TOP PICK

Could be some tax loss selling and would hope that it would drop to $23.50. Would buy a lot if that happened. Would buy some at the current price also.

WAIT

Taking a hard look at it but haven't made a decision. Has real earnings and is quite profitable. It hinges on their success going forward with new drugs they are developing.

BUY

Street wants to hate this stock. They've warned twice and have missed their earnings. Have some drugs that are performing better. Taking into account that earnings may have been aggressively stated, it is still trading cheaply.

DON'T BUY

Have problems. There are a lot of short-sellers on this one.

DON'T BUY

Accounting practices are under review. There are also concerns about the lack of disclosure by management.

DON'T BUY

A crash and burn stock. Charts indicate problems, so if you buy, keep a real tight stop on it. Could drop further.

DON'T BUY

Have had a number of problems and feels there are probably more. So many question marks involving the Company, its accountings, corporate governance, rate of sales of products, growth, etc.

DON'T BUY

The story is one of credibility and confidence towards management. An above average risk. There is less visibility in the predictability of earnings. Needs one or two strong quarters for investors to gain confidence.

DON'T BUY

Just too many problems with respect to the profit and loss.

Showing 496 to 510 of 714 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Keith Richards

ValueTrend Wealth Management

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Valeant Pharmaceuticals (VRX.TO)